The Company entered into an agreement with "KSL". The aggregate principal amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company's common stock and warrants for a purchase price of $270,272. As of December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company's common stock.

15.99%

15.89%

Long-Term Investments (Details Textual)		12 Months Ended
Long-Term Investments (Details Textual)	Nov. 09, 2020	Dec. 31, 2020	Dec. 31, 2019
Long-Term Investments (Textual)
Sale of common stock, description	The Company entered into an agreement with "KSL". The aggregate principal amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company's common stock and warrants for a purchase price of $270,272. As of December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company's common stock.
Rgene [Member]
Long-Term Investments (Textual)
Percentage of common stock shares		31.62%	31.61%
BioFirst [Member]
Long-Term Investments (Textual)
Percentage of common stock shares		15.99%	15.89%
Sale of common stock, description		The Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the same period.